J&J says AI cuts drug lead development time in half
Johnson & Johnson says artificial intelligence is reducing by 50% the time needed to generate early drug development leads, accelerating how quickly promising compounds are identified.
According to J&J, AI is helping screen large pools of chemical and biologic candidates faster, improving lead optimization in areas such as cancer and immunology. The company says it has already sped up development for two compounds.
AI is also transforming operations beyond discovery:
- Clinical trial documentation reduced from hundreds of hours to minutes
- Faster patient recruitment
- Improved manufacturing efficiency
- Enhanced surgical precision in medical devices
J&J says AI is not yet replacing full drug discovery, but it is becoming a major force multiplier in speeding research, regulatory workflows and treatment innovation.
